Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine administered during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and passing protection through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.

How the immunisation protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”

The pregnancy vaccine operates by activating the mother’s immune system to produce defence proteins, which are then passed to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The new study shows that protection reaches nearly 85 per cent when the vaccine is administered at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.

• Nearly 85 per cent coverage when vaccinated 4 weeks before birth
• Maternal antibodies passed through the placenta safeguard newborns from birth
• Coverage possible with two-week gap before early delivery
• Vaccination during third trimester still provides meaningful infant protection

Strong evidence from recent research

The performance of the RSV vaccine administered during pregnancy has been demonstrated through a extensive research programme carried out throughout England, reviewing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month timeframe, providing comprehensive and reliable evidence of the vaccine’s real-world impact. The study’s findings have been validated by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scope of this study offers healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across different groups and contexts.

The results paint a notable picture of the vaccine’s protective effectiveness. More than 4,500 babies were hospitalised with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This marked difference underscores the vaccine’s vital importance in reducing the risk of serious illness in newborns. The reduction in hospital admissions surpassing 80 per cent represents a major public health success, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.

Study methodology and scope

The research reviewed birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The substantial sample size and thorough nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than isolated cases or limited subgroups.

The study specifically monitored hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with shorter intervals. The methodology captured real-world outcomes rather than controlled laboratory conditions, providing real-world data of how the vaccine works when delivered across different clinical contexts and patient circumstances throughout the third trimester of pregnancy.

Learning about RSV and its risks

Respiratory syncytial virus, typically known as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity varying dramatically from minor cold-type symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on children’s wards and newborn care units during peak seasons.

The infection triggers deep inflammation in the lungs and airways, making it dangerously difficult for affected infants to breathe and feed properly. Parents commonly see their babies fighting for breath, their chests rising whilst they work to get adequate oxygen into their compromised lungs. Whilst the majority of babies recover with clinical support, a modest yet notable number die from RSV complications each year, making immunisation programmes a vital health service priority for protecting the most vulnerable and youngest individuals in the population.

• RSV produces inflammation in lungs, causing severe breathing difficulties in babies
• Nearly 50% of newborns catch the infection during their first few months alive
• Symptoms range from mild colds to life-threatening chest infections needing hospital treatment
• Over 20,000 UK babies require serious hospital care for RSV each year
• Few infants succumb to RSV complications each year in the UK

Take-up rates and expert recommendations

Since the RSV vaccine programme launched in 2024, health officials have stressed the importance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for guaranteeing newborns receive the maximum immunity from birth. Whilst the study demonstrates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts encourage women to get their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies via the placenta.

The guidance from public health bodies stays clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst ensuring strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV represents the highest danger of serious illness.

Regional disparities in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and implementation timelines have varied across various areas and NHS trusts. Certain regions have attained higher vaccination coverage among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These regional differences demonstrate differences across medical facilities, communication strategies, and community involvement initiatives, though the national data shows consistently strong protection irrespective of geographical location.

• NHS trusts deploying multiple messaging strategies to reach women during pregnancy
• Regional disparities in immunisation take-up across England require targeted improvement
• Regional health providers tailoring initiatives to meet specific population needs

Practical implications and parental perspectives

The vaccine’s impressive effectiveness delivers tangible benefits for families throughout the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the launch of this protective measure, the 80% reduction in admissions means thousands of infants shielded from severe infection. Parents no more face the distressing scenario of seeing their babies gasping for air or struggle to eat, symptoms that define critical RSV illness. The vaccine has substantially transformed the terrain of neonatal respiratory health, giving expectant mothers a active means to shield their most vulnerable children during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection led to severe brain damage, the vaccine’s availability carries deep personal significance. His mother’s support of the jab emphasises the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now largely avoidable has provided considerable reassurance to women in pregnancy in their late pregnancy, changing what was once an unavoidable seasonal threat into a manageable risk.